MOLECULAR PROFILE AND ANTI-TUMOR ACTIVITY IN NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS (PTS) IN A PHASE 1 STUDY OF CABOZANTINIB (XL184) IN JAPAN

被引：0
|
作者：
Nokihara, H. [1 ]
Yamamoto, N. [1 ]
Nakamichi, S. [1 ]
Wakui, H. [1 ]
Yamada, Y.
Frye, J. [2 ]
Decillis, A. [2 ,3 ]
Tamura, T. [4 ]
机构：
[1] Natl Canc Ctr, Div Thorac Oncol, Tokyo, Japan
[2] Exelixis Inc, Med Affairs, San Francisco, CA USA
[3] Exelixis Inc, Clin Dev, San Francisco, CA USA
[4] Natl Canc Ctr, Div Internal Med & Thorac Oncol, Tokyo, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：174 / 174
页数：1
相关论文
共 50 条
  • [1] Phase 2 results of XL184 in a cohort of patients (pts) with advanced non-small cell lung cancer (NSCLC)
    Yasenchak, C.
    Nackaerts, K.
    Awada, A.
    Gadgeel, S. M.
    Hellerstedt, B.
    Perry, M. C.
    Richards, D.
    Yang, C. H.
    Scheffold, C.
    Lara, P. N., Jr.
    EJC SUPPLEMENTS, 2010, 8 (07): : 126 - 126
  • [2] A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
    Heather A. Wakelee
    Scott Gettinger
    Jeffrey Engelman
    Pasi A. Jänne
    Howard West
    Deepa S. Subramaniam
    Joseph Leach
    Michael Wax
    Yifah Yaron
    Dale R. Miles
    Primo N. Lara
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 923 - 932
  • [3] A phase Ib/II study of cabozantinib (XL184) with or without erlotinib in patients with non-small cell lung cancer
    Wakelee, Heather A.
    Gettinger, Scott
    Engelman, Jeffrey
    Janne, Pasi A.
    West, Howard
    Subramaniam, Deepa S.
    Leach, Joseph
    Wax, Michael
    Yaron, Yifah
    Miles, Dale R.
    Lara, Primo N., Jr.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (05) : 923 - 932
  • [4] A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).
    Wakelee, H. A.
    Gettinger, S. N.
    Engelman, J. A.
    Janne, P. A.
    West, H. J.
    Subramaniam, D. S.
    Leach, J. W.
    Wax, M. B.
    Yaron, Y.
    Lara, P., Jr.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [5] Anti-tumor activity observed in an ongoing phase 1 drug-drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma
    Choueiri, T. K.
    Pal, S. K.
    McDermott, D. M.
    Ramies, D. A.
    Morrissey, S.
    Lee, Y.
    Miles, D.
    Holland, J. S.
    Dutcher, J. P.
    BJU INTERNATIONAL, 2012, 109 : 4 - 4
  • [6] A phase I study of cabozantinib (XL184) in patients with renal cell cancer
    Choueiri, T. K.
    Pal, S. K.
    McDermott, D. F.
    Morrissey, S.
    Ferguson, K. C.
    Holland, J.
    Kaelin, W. G.
    Dutcher, J. P.
    ANNALS OF ONCOLOGY, 2014, 25 (08) : 1603 - 1608
  • [7] Activity of cabozantinib (XL184) in advanced ovarian cancer patients (pts): Results from a phase II randomized discontinuation trial (RDT).
    Buckanovich, R. J.
    Berger, R.
    Sella, A.
    Sikic, B. I.
    Shen, X.
    Ramies, D. A.
    Smith, D. C.
    Vergote, I. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [8] Phase 1b Trial of Cabozantinib or Cabozantinib Plus Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
    Lim, F.
    Ponce, S.
    Patel, S.
    Van Herpen, C.
    Kurkjian, C.
    Lou, Y.
    Liu, Y.
    Ramsingh, G.
    Pal, S.
    Neal, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S405 - S406
  • [9] CNS activity of ensartinib in ALK1 non-small cell lung cancer (NSCLC) patients (pts)
    Reckamp, K. L.
    Wakelee, H. A.
    Patel, S.
    Blumenschein, G.
    Neal, J. W.
    Gitlitz, B.
    Waqar, S. N.
    Tan, F.
    Harrow, K.
    Horn, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [10] Antitumor activity observed in a phase I drug-drug interaction study of cabozantinib (XL184) and rosiglitazone in patients (pts) with renal cell carcinoma (RCC) and differentiated thyroid cancer (DTC)
    Choueiri, T. K.
    Pal, S. K.
    Cabanillas, M. E.
    Ramies, D. A.
    Tseng, L.
    Holland, J. S.
    Morrissey, S.
    Dutcher, J. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
12345